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Boulle et al.1 queried whether a clinical trial was needed to provide 
the evidence for the mortality benefits of antiretroviral therapy (ART) 
initiation during tuberculosis (TB) treatment. While several experts, 
including foremost TB-HIV scientists from South Africa2 and the 
USA,3 senior World Health Organization (WHO)4 and UNAIDS5 
officials at the time the study was initiated, the 2003 WHO AIDS 
Treatment Guidelines Committee Chair3, the Chair of the Ethics 
Committee6 and the researchers,7 have previously addressed the 
points raised, the SAPIT (Starting Antiretroviral Therapy at Three 
Points in Tuberculosis) research team welcomes the opportunity 
also to address the comments. We hold Boulle and his colleagues in 
high regard and appreciate their contributions to the field of HIV 
and tuberculosis co-infection. More importantly, we share with them 
the common goal of rigorously and relentlessly seeking answers to 
critically important research questions as we confront the devastating 
dual AIDS and tuberculosis epidemics.
The SAPIT trial,8 which was developed in 2004, set out to assess 
whether integrating tuberculosis and AIDS treatment would lead to 
improved outcomes compared with the widely practised approach of 
treating them sequentially. The trial’s Safety Monitoring Committee 
halted the sequential treatment arm in September 2008 because 
of a 56% lower mortality rate in the integrated treatment arm. We 
systematically address the queries on equipoise and standard of care.
Did the SAPIT study have clinical 
equipoise?
Yes, the optimal timing of ART initiation in patients with tuberculosis 
was not known at the time the trial was planned and conducted.
Availability of, and experience in providing, ART in developing 
countries, including South Africa, was limited before 2004, and even 
less was known about the timing of ART initiation in tuberculosis-
HIV co-infected patients. Treatment guidelines were either silent 
on this issue or contained tentative and provisional guidance largely 
based on expert opinion, due to the lack of reliable and compelling 
evidence. The 2003 WHO guidelines specifically mention this 
limitation and that their recommendations are ‘Pending ongoing 
studies ...’.9
The SAPIT trial had clinical equipoise because the balance between 
the potential increase in morbidity and mortality due to combined 
antiretroviral-tuberculosis drug intolerance, drug-drug interactions 
and immune reconstitution inflammatory syndrome (IRIS) on the 
one hand and the potential improved morbidity and mortality from 
early antiretroviral initiation on the other were unknown.9 Published 
data on IRIS-associated morbidity and mortality at the time were 
limited, not least owing to substantial under-reporting resulting from 
the lack of a consistent case definition of what constituted IRIS. A 
WHO consultation10 in 2005 highlighted the problem of inadequate 
data on IRIS and recommended that ‘validating the definition of 
IRIS’ be regarded as a research priority. When the standardised 
case definition of IRIS was published in 2008, the authors pointed 
out that this definition will help clinicians by providing insight into 
the incidence, clinical manifestations and impact of TB-associated 
IRIS.11 
Boulle et al. cite two retrospective chart review studies12-13 
undertaken in the UK to support their argument that the beneficial 
effect of ART during TB therapy was already known. The first 
included 159 patients with TB and HIV who were not on ART at 
presentation, 45% of whom were subsequently initiated on ART by 
the treating clinicians.12 Just over a third of the latter patients had 
either TB or HIV treatment discontinued because of adverse events, 
making interpretations of safety and effectiveness difficult. The 
second compared outcomes in 36 patients with TB and HIV in a 
pre-antiretroviral era with 60 patients in the antiretroviral era.13 Both 
studies provide useful initial descriptive information on experiences 
in co-treatment, but do not provide the quality of evidence essential 
for the development of clinical guidelines and treatment policy. 
Some co-treatment challenges are epitomised in the statement: ‘More 
doubts than certainties are available on which basing the decision on 
how to cope therapeutically with active tuberculosis developing in a 
patient also requiring antiretroviral treatment.’14
The existence of equipoise was confirmed by several levels of 
scientific, regulatory and ethical review, including independent 
approval from the Medicines Control Council and the Biomedical 
Research Ethics Committee of the University of KwaZulu-Natal 
(a US Office for Human Research Protections-accredited ethics 
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the co-authors of the critique.1 The SAPIT trial was undertaken 
after widespread consultation in scientific and community forums, 
including presentations and dedicated sessions at the South African 
AIDS conferences in 2003 and 2005. Importantly, a rationale for 
the trial was published in the peer-reviewed literature before its 
initiation.15
Were the patients in the SAPIT trial 
provided the best standard of care? 
Yes, the SAPIT trial provided the prevailing best standard of care 
for antiretroviral initiation, viz. clinician judgement. Clinicians with 
prior experience in treating TB-HIV co-infected patients were in a 
position throughout the study to initiate patients (who were seen 
daily during the week in the directly observed treatment programme) 
on ART at any time, based on their clinical judgement. 
On their point of adequacy of the standard of care provided to 
patients in the SAPIT trial, Boulle et al.1 quote from the World 
Medical Association’s Declaration of Helsinki:16 ‘… “the best current” 
intervention should be provided as the standard of care to patients in 
studies …’. In doing so, they omit the crucial word ‘proven’; paragraph 
32 of the current Declaration (quoted and referenced in their article) 
stated in full is: ‘The benefits, risks, burdens and effectiveness of a 
new intervention must be tested against those of the best current 
proven intervention ...’ (our italics).  
While it was well recognised that HIV and TB co-infected patients 
with low CD4+ counts had a higher mortality, it was not proven that 
early antiretroviral initiation in TB co-infected patients improved 
morbidity and mortality. The 2003 WHO AIDS treatment guidelines, 
which informed the 2004 South African AIDS treatment guidelines, 
stated clearly that recommendations on the initiation of ART in TB 
co-infected patients were ‘provisional’, since the ‘optimal time to 
initiate [antiretroviral agents] in patients with [tuberculosis] is not 
known’.17 Such tentative guidance cannot be considered a proven 
intervention. To further confirm that that this was not proven, a 
WHO consultation in 2005 on management of patients with HIV and 
TB concluded that the optimal time for initiating ART in HIV and TB 
co-infected patients is ‘the major research priority’.10 
Was this trial needed for tuberculosis 
and HIV treatment?
Yes, the SAPIT trial informed the new WHO treatment guidelines.
Retrospective chart reviews, such as cited by Boulle et al. in support 
of initiation of ART during TB treatment, are seldom regarded as 
sufficient evidence for authoritative treatment guidelines, as they are 
prone to many biases and are rarely effective in influencing clinician 
practices. In 2009, the WHO guidelines18 were updated to provide 
definitive advice on the timing of antiretroviral initiation in patients 
with TB and HIV, drawing upon the results of the SAPIT trial. 
On World AIDS Day in 2009, the South African government also 
announced19 a change in TB-HIV co-treatment guidelines, drawing 
on the SAPIT trial results. 
The SAPIT trial provided the essential evidence on the risks and 
benefits on integrated HIV and TB treatment to guide clinicians and 
inform both global and local policy on HIV and TB treatment. We 
now have the collective opportunity and the responsibility to ensure 
that patients with TB and HIV are rapidly diagnosed and are initiated 
on ART during TB treatment.
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